Companies Dominating the Rituximab Landscape
- Amgen Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Henlius Biotech, Inc.
- Nordic Nanovector ASA
- Biocon Biologics Ltd
- Pfizer Inc.
- Chugai Pharmaceuticals
- Zenyaku Kogyo Co. Ltd,
- SymBio Pharmaceuticals
- Daiichi Sankyo
- Kyowa Kirin Co. Ltd
Browse Key Market Insights with Data Illustration:
In the News
- Nordic Nanovector ASA announced the successful outcomes of the Archer-1 phase B trial for treating second-line follicular lymphoma (2L FL), investing Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab (RTX).
- Biocon Biologics Ltd has signed an agreement with the Clinton Health Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP).
